News
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Warehouse REIT plc
Form 8.3 - The Vanguard Group, Inc.: Warehouse REIT plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Spirent Launches Scalable Over-the-Air Solution to Enable True End-to-End Network Testing with Real Handsets
Spirent Communications plc (LSE:SPT), a leading provider of test and assurance solutions for next-generation devices and networks, today announced the launch of the Landslide E20 Over-the-Air (OTA)
Halfords Group PLC: Preliminary Results for the 52 weeks to 28 March 2025
Halfords Group PLC: Preliminary Results for the 52 weeks to 28 March 2025
Form 8.3 - The Vanguard Group, Inc.: ME Group International plc
Form 8.3 - The Vanguard Group, Inc.: ME Group International plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Halfords Group PLC: Notice of Preliminary Results announcement
Halfords Group PLC: Notice of Preliminary Results announcement
Form 8.3 - The Vanguard Group, Inc.: ME Group International plc
Form 8.3 - The Vanguard Group, Inc.: ME Group International plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data